Estamos no ar no ! Saiba mais
294,66 USD
+1,43
0,49%
No fechamento Atualizado 16 de out. 16:00 EDT
Pré-mercado
Após o fechamento do mercado
295,00
+0,34
0,12%
1 dia
0,49%
5 dias
6,26%
1 mês
3,48%
3 meses
-11,03%
6 meses
-12,92%
No acumulado do ano
-15,37%
1 ano
-20,2%
5 anos
12,44%
10 anos
159,45%
 

Sobre: Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, mechanical thrombectomy systems, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Roughly one-fourth of Stryker's total revenue currently comes from outside the United States.

Funcionários: 56.000

Notícias

Positivo
Neutro
Negativo
Sentimento 3 meses
Positivo 39,1%
Neutro 56,5%
Negativo 4,3%
Neutro
GlobeNewsWire
ontem
Securities Fraud Investigation Into Stryker Corporation (SYK) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
LOS ANGELES, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Stryker Corporation (“Stryker” or the “Company”) (NYSE: SYK) investors concerning the Company's possible violations of the federal securities laws.
Securities Fraud Investigation Into Stryker Corporation (SYK) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Neutro
PRNewsWire
ontem
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Stryker Corp. - SYK
NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Stryker Corp. ("Stryker" or the "Company") (NYSE: SYK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Stryker Corp. - SYK
Neutro
GlobeNewsWire
ontem
Stryker Corporation (SYK) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
BENSALEM, Pa., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G.
Stryker Corporation (SYK) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Neutro
GlobeNewsWire
anteontem
Securities Fraud Investigation Into Stryker Corporation (SYK) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
LOS ANGELES, Oct. 14, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its investigation of Stryker Corporation (“Stryker” or the “Company”) (NYSE: SYK) on behalf of investors concerning the Company's possible violations of federal securities laws.
Securities Fraud Investigation Into Stryker Corporation (SYK) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
Neutro
PRNewsWire
anteontem
Stryker launches Sonopet® 3, delivering greater power and precision in ultrasonic tissue removal
Stryker has received FDA 510(k) clearance for Sonopet ® 3 , the latest evolution of its ultrasonic bone and soft tissue removal platform. Developed in collaboration with surgeons, Sonopet 3 delivers enhanced power, precision and versatility.
Stryker launches Sonopet® 3, delivering greater power and precision in ultrasonic tissue removal
Neutro
GlobeNewsWire
há 3 dias
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Stryker Corp. - SYK
NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Stryker Corp. (“Stryker” or the “Company”) (NYSE: SYK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Stryker Corp. - SYK
Positivo
Seeking Alpha
há 4 dias
Stryker: Q2 Recovery And Portfolio Expansion Strengthen The Operating Story
Stryker rebounded in 2Q26, with operating momentum restored after the prior quarter's cybersecurity disruption. 2Q26 sales rose 9.4% YoY to ~$6.6 billion; organic growth reached ~9%, demonstrating resilience despite earlier headwinds. Adjusted EPS increased ~18% to $3.69, and operating margin expanded 170 bps to 27.4%, reflecting improved profitability.
Stryker: Q2 Recovery And Portfolio Expansion Strengthen The Operating Story
Neutro
PRNewsWire
há 8 dias
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Stryker Corp. - SYK
NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Stryker Corp. ("Stryker" or the "Company") (NYSE: SYK).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Stryker Corp. - SYK
Neutro
GlobeNewsWire
há 10 dias
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Stryker Corp. - SYK
NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Stryker Corp. (“Stryker” or the “Company”) (NYSE: SYK).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Stryker Corp. - SYK
Negativo
Investors Business Daily
há 10 dias
Stryker, Neogenomics Announce CEO Transitions; But One Stock Dives
Stryker and Neogenomics stocks diverged Tuesday after the medtech companies announced their chief executives would soon step down.
Stryker, Neogenomics Announce CEO Transitions; But One Stock Dives
Gráficos de preços implementados com Lightweight Charts™